DBV Technologies Announces the Results of its 2026 Combined General Meeting

DBV Technologies (Nasdaq: DBVT) held its 2026 Combined General Meeting in Châtillon, France, on June 3, 2026.

Rhea-AI Summary

DBV Technologies (Nasdaq: DBVT) held its 2026 Combined General Meeting in Châtillon, France, on June 3, 2026. The meeting was chaired by Michel de Rosen, Chairman of the Board of Directors.

Shareholders approved all resolutions submitted by the Board. Detailed resolutions and voting results are available on the company’s website.

Argus Jun 4 session

-0.68% close to close Open Argus

Details

News Market Reaction – DBVT

In the Jun 4 session, DBVT declined 0.68%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement confirms that shareholders approved all resolutions at the 2026 Combined General M...

Analysis

This announcement confirms that shareholders approved all resolutions at the 2026 Combined General Meeting, aligning with prior communications about the meeting and proxy process. It primarily addresses governance continuity rather than new clinical or financial data. In recent months, DBV highlighted cash levels, losses, and progress toward regulatory filings. Investors following this story may watch upcoming clinical milestones, regulatory submissions, and future earnings for more directional information than routine AGM outcomes provide.

Key Figures

AGM year: 2026 AGM date: June 3, 2026

AGM year

2026

Year of the Combined General Meeting referenced in the announcement

AGM date

June 3, 2026

Date the 2026 Combined General Meeting was held in Châtillon

Historical Context

5 past events · Latest: May 13

5 events

1. May 13

   AGM announcement

   24h Move

   +1.2%

   Outlined June 3, 2026 Combined General Meeting logistics and materials access.

2. May 12

   Conference participation

   24h Move

   -2.0%

   Disclosed CEO fireside chat at H.C. Wainwright BioConnect investor conference.

3. Apr 30

   Quarterly earnings

   24h Move

   -5.4%

   Reported Q1 2026 loss and spending increases alongside cash position update.

4. Apr 02

   Share count update

   24h Move

   -3.3%

   Published total shares and voting rights as of March 31, 2026.

5. Mar 26

   Annual filings

   24h Move

   -1.0%

   Filed 2025 Form 10-K and 2025 Universal Registration Document with regulators.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

isin

1 terms

isin financial

"DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT)"

A 12-character International Securities Identification Number (ISIN) is a unique code that acts like a passport for a specific stock, bond or other tradable security so it can be identified worldwide. Investors and systems use it to ensure they are buying, selling and tracking the exact same instrument across exchanges and data feeds, which prevents costly mix-ups and makes portfolio reporting, settlement and regulatory checks simpler and more reliable.

View in glossary

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Châtillon, France, June 3, 2026

DBV Technologies Announces the Results of its 2026 Combined General Meeting

Shareholders approved all proposed resolutions

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a late stage biopharmaceutical company (the “Company”), held its Combined General Meeting (the “General Meeting”). The General Meeting was chaired by Michel de Rosen, Chairman of the Board of Directors (the “Board”).

The Company’s shareholders approved all resolutions submitted by the Board.

The resolutions and voting results are posted on the Company’s website: 2026 Annual General Meeting | DBV Technologies

About DBV Technologies
DBV Technologies is a late-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with significant unmet medical need. DBV Technologies is currently focused on investigating the use of its proprietary VIASKIN^® patch technology to address food allergies, which are caused by a hypersensitive immune reaction and characterized by a range of symptoms varying in severity from mild to life-threatening anaphylaxis. Millions of people live with food allergies, including young children. Through epicutaneous immunotherapy (EPIT), the VIASKIN^® patch is designed to introduce microgram amounts of a biologically active compound to the immune system through intact skin. EPIT is a new class of non-invasive treatment that seeks to modify an individual’s underlying allergy by re-educating the immune system to become desensitized to allergen by leveraging the skin’s immune tolerizing properties. DBV Technologies is committed to transforming the care of food allergic people. The Company’s food allergy programs include ongoing clinical trials of the VIASKIN Peanut Patch in peanut allergic toddlers (1 through 3 years of age) and children (4 through 7 years of age).

DBV Technologies is headquartered in Châtillon, France, with North American operations in Warren, NJ. The Company’s ordinary shares are traded on segment B of Euronext Paris (DBV, ISIN code: FR0010417345) and the Company’s ADSs (each representing five ordinary shares) are traded on the Nasdaq Capital Market (DBVT – CUSIP: 23306J309).

For more information, please visit www.dbv-technologies.com and engage with us on X (formerly Twitter) and LinkedIn.

VIASKIN is a registered trademark of DBV Technologies.

Investor Contact
Jonathan Neely
DBV Technologies
jonathan.neely@dbv-technologies.com      

Media Contact
Brett Whelan
DBV Technologies
brett.whelan@dbv-technologies.com

Attachment

• PDF Version

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What were the results of DBV Technologies (DBVT) 2026 Combined General Meeting?

DBV Technologies shareholders approved all resolutions at the 2026 Combined General Meeting. According to DBV Technologies, every proposal submitted by the Board of Directors received shareholder approval, and detailed voting results are published on the company’s website for investor review.

When and where did DBV Technologies hold its 2026 Combined General Meeting?

DBV Technologies held its 2026 Combined General Meeting on June 3, 2026, in Châtillon, France. According to DBV Technologies, the session gathered shareholders to vote on all proposed resolutions and confirm corporate decisions recommended by the Board of Directors.

Who chaired DBV Technologies 2026 Combined General Meeting for DBVT shareholders?

The 2026 Combined General Meeting was chaired by Michel de Rosen, Chairman of the Board. According to DBV Technologies, he presided over the session during which shareholders voted on and approved all resolutions submitted by the Board of Directors.

Where can investors find DBV Technologies 2026 general meeting resolutions and voting results?

Investors can access the 2026 resolutions and voting results on DBV Technologies’ website. According to DBV Technologies, the detailed documents are posted under the 2026 Annual General Meeting section for shareholder transparency and regulatory information purposes.

Did DBV Technologies shareholders reject any resolutions at the 2026 Combined General Meeting?

DBV Technologies shareholders did not reject any resolutions at the 2026 meeting. According to DBV Technologies, all resolutions submitted by the Board of Directors to the Combined General Meeting were approved and the final voting breakdown is available online.